This supplement request is for a Phase 3, randomized, observer-blind, placebo-controlled study to evaluate the efficacy, safety and immunogenicity, of a SARS-CoV-2 recombinant spoke protein nanoparticle vaccine (SARS-CoV-2 rS) with Matric-M1TM adjuvant in adult participants over 18 years of age who have no known history of SARS-CoV-2 infection but whose locations or circumstances put them at appreciable risk of acquiring COVID-19 and/or SARS-CoV-2 infection. This request also relates to other COVID 19 activities.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
3UM1AI148575-02S4
Application #
10296949
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Lee, Marina
Project Start
2020-12-23
Project End
2022-11-30
Budget Start
2020-12-23
Budget End
2021-11-30
Support Year
2
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Baylor College of Medicine
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030